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Assessment of techniques to reduce sclerosant
foam migration during ultrasound-guided
sclerotherapy of the great saphenous vein
Douglas Hill, MD, FACPh,a Rhonda Hamilton, RDMS, RDCS,a and Tak Fung, PhD,b Calgary, Alberta,
Canada
Background: Endovenous chemical ablation is a technique for treatment of great saphenous vein insufficiency. However,
echogenic phenomena in the right heart and high intensity transient signals detected by transcranial Doppler have been
described subsequent to foam sclerotherapy. An ischemic event after foam sclerotherapy of the great saphenous vein was
reported recently in a patient with an occult patent foramen ovale. Another concern is the effects of sclerosant foam on
the pulmonary microvasculature.
Objective: This study is a retrospective report comparing the utility of three commonly used techniques for reducing
sclerosant foam migration during ultrasound-guided sclerotherapy of the great saphenous vein.
Methods: Group 1 consisted of 20 patients treated with ultrasound-guided foam sclerotherapy of the great saphenous vein
while lying supine, with digital pressure used to occlude the saphenofemoral junction. In group 2, 19 patients underwent
injection while the leg was elevated 30°, with digital pressure at the saphenofemoral junction. Group 3 comprised 19
patients injected while the leg was elevated but without manual compression at the saphenofemoral junction. All patients
were monitored with subcostal echocardiography during the injection and for 3 to 5 minutes after.
Results: Echogenic phenomena were demonstrated in the right heart in all 20 patients in group 1, in 16 of 19 in group 2,
and in nine of 19 in group 3. There was a statistically significant difference in the incidence of echogenic phenomena
between groups 1 and 3 using the Fisher exact test (P < .001). A significant difference in incidence was also present when
groups 2 and 3 were compared (P < .038). In groups 1 and 2, a concentrated bolus of bubbles was frequently observed
after release of digital pressure; however, less intense echogenic phenomena were seen in group 3 where injection was
performed with the leg elevated but without manual pressure at the saphenofemoral junction. No echogenic phenomena
were observed in the left heart, and no complications occurred. Short-term treatment results were equivalent among the
three groups.
Conclusions: Ultrasound-guided sclerotherapy of the great saphenous vein using foam sclerosants is best performed with
the leg elevated and no occlusive pressure at the saphenofemoral junction in order to reduce the risk of gas embolization
to the central nervous system. Further study is needed to assess the midterm success of this technique and to confirm the
effect of using foam produced from physiologic gases. ( J Vasc Surg 2008;48:934-9.)Ultrasound-guided foam sclerotherapy has become an
increasingly accepted minimally invasive alternative to sur-
gery or endovenous thermal ablation for treatment of great
saphenous vein incompetence.1 The low complication rate
of sclerotherapy with liquid or foam has been documented
in a large multicenter study. Of note however, more com-
plications occurred with foam compared with liquid, and
visual disturbance was reported four times more frequently
with foam.2 A study of 662 patients injected with Varisolve
microfoam (BTG International, West Conshohocken Pa)
or air foam reported six incidents of transient, nonspecific
neurologic symptoms, including paresthesias, visual com-
plaints, and speech disorders.3
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934Although the overall risk of foam sclerotherapy appears
to be low, concern has persisted about the possibility of
pulmonary toxicity4 and central nervous system complica-
tions in the setting of a patent foramen ovale.5 The reality
of sclerosant foam trapping in the lung was demonstrated in
a recent study.6 Concerns about gas embolism through a
right to left shunt have been heightened by a recent report
of a stroke in a 61-year-old man after ultrasound-guided
foam sclerotherapy.7 This patient was subsequently found
to have a large patent foramen ovale.
In a relevant mail-in survey sent to members of the
Vascular Society of Great Britain and Ireland, two of 70
surgeons reported having seen a stroke while administering
foam sclerotherapy, and one described a transient ischemic
attack.8 Echocardiography after foam sclerotherapy has
repeatedly demonstrated echogenic phenomena in the
heart, and transcranial Doppler regularly detects high-
intensity transient signals in the presence of a right to left
cardiac shunt.9-11
Numerous factors can influence the behavior of foam in
the venous system after injection, including volume and
composition of the foam as well as the injection technique
itself. Leg elevation has been recommended12 but is not
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appears to be no general consensus in practice. In the case
reported by Forlee et al,14 10 mL of polidocanol foam was
injected with the leg horizontal while the saphenofemoral
junction was compressed. The leg was then elevated, and a
further 10 mL of foam was injected.14 In O’Hare and
Earnshaw’s survey of the Vascular Society of Great Britain
and Ireland, 69% of practitioners using foam reported
elevating the leg before injection, whereas 63% blocked the
saphenofemoral or saphenopopliteal junction before injec-
tion.8 Some practitioners report foam injection with the
patient supine and pressure subsequently applied at the
saphenous junction.15 The Varisolve technique as de-
scribed in 2006 involved compression at the junction when
the foam was observed to reach that level.3 Other authors
report injecting foam with the leg level and then elevating
the leg when the foam progresses to the saphenofemoral
junction.16 A recent article has suggested balloon occlusion
of the saphenofemoral junction before injection to prevent
sclerosant foam leakage into the deep venous system.17
This approach has been criticized as ineffective and possibly
exacerbating foam embolization.18
In summary, expert opinion is divided on the advan-
tages and disadvantages of compression at the junctions
during foam sclerotherapy of the saphenous veins.13 A
MEDLINE search found no published reports comparing
different techniques of foam injection sclerotherapy for
their effects on foam migration. This study presents the
results of echocardiographic assessment of the right atrium
and ventricle obtained for three cohorts of patients in
whom different techniques of ultrasound-guided foam
sclerotherapy were used.
METHODS
This was a nonrandomized retrospective study. The
sample consisted of patients in a private phlebology practice
presenting with great saphenous vein or accessory great
saphenous vein incompetence who chose to be treated with
ultrasound-guided foam sclerotherapy and consented to a
cardiac scan after injection as part of ongoing quality of care
assessment. Specific exclusion criteria for the study were the
presence of a cardiac murmur or a known atrial or ventric-
ular septal defect, saphenous veins with thigh perforating
veins evident proximal to the injection site, patients treated
with 2 mL of foam, and patients with poor quality echo-
cardiographic studies due to body habitus. The study in-
cluded 58 legs of 57 patients (51 women, 6 men). One
patient had both legs injected. Themean age of the patients
was 50 years (range, 21-75 years). The CEAP clinical class
was C2 for 46 limbs and C3 for 12. Treated in the study
were 55 great saphenous veins, two accessory great saphe-
nous veins, and one postsurgical saphenous recurrence.
All patients were assessed in an upright position with
duplex ultrasound in a separate assessment appointment
before treatment. Superficial veins were mapped, and com-
petence was assessed with color flow and pulsed wave
Doppler. Saphenous vein diameter 2 cm below the saphe-
nofemoral junction, at midthigh, and at the knee wasmeasured with the patient standing. Saphenous vein in-
competence was defined as spectral Doppler reflux lasting
0.5 seconds after calf compression and release. The deep
venous system was also assessed for patency and compe-
tence.
Informed consent was obtained for ultrasound-guided
foam injection and a treatment session was scheduled. To
begin the initial treatment session, the patient was seated in
a semirecumbent position, and the saphenous vein was
cannulated in the vicinity of the knee or at the most distal
point where the vein remained intrafascial. Venipuncture
was performed under ultrasound guidance using a 1.25- to
2-inch 20-gauge angiocatheter. The location of great sa-
phenous vein cannulation for each patient was recorded as
proximal, middle, or distal one-third of the thigh. Once
intravenous placement of the catheter was confirmed, the
patient was reclined to a supine position by lowering the
back of the examination table.
For most patients, the sclerosant used for foam pro-
duction was sodium tetradecyl sulfate in sclerosant con-
centrations of 1.5% to 3% depending on the size of the vein
being treated. One patient was treated with 3% polidocanol
due to a possible allergy to sodium tetradecyl sulfate. Room
air was use to create the foam sclerosant for 46 patients and
12 patients were treated with carbon dioxide (CO2)–based
foam.
Foam was produced using a modified Tessari method.19
Air-based foam was produced using a 3-mL syringe joined
to a 6-mL syringe by a Luer lock connector. The CO2 foam
was created with a 3-mL syringe connected to a 6-mL
syringe by a three-way stopcock interposed with a 5-m
syringe filter.
Liquid sclerosant and room air or CO2 were mixed in a
combination of 1:4 by the application of 20 back and forth
passes of the mixture. The foam was immediately injected
into the target vessel through the catheter already in place.
Injection was performed slowly in a controlled manner to
allow the foam to progress slowly up the vein at a rate of
about 1 cm/s as monitored continuously by ultrasound.
The injection was terminated when the foam was observed
to reach the saphenofemoral junction. The volume of foam
used was recorded.
The foam volume required to fill the vein was judged to
be the most accurate approximation of the dimensions of
the vein at the time of treatment because the vein diameter
was observed to be a very inconsistent and unstable vari-
able, changing segmentally in response to catheterization as
well as being markedly altered with repositioning of the
patient’s limb. This variability meant that no useful direct
calculation of the vein volume at the time of treatment was
attainable. During the initial treatment session, only the
intrafascial segment of the great saphenous vein was treated
according to our standard practice. Incompetent accessory
saphenous veins and extrafascial varicose tributaries were
treated during a follow-up session 1 month later.
After foam injection, the right atrium and ventricle
were continuously monitored through a subcostal ap-
proach for up to 5 minutes using a Prosound 3500 (Aloka
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Patients were asked to remain still during the cardiac mon-
itoring and avoid voluntary muscle contractions. No pro-
vocative maneuvers such as Valsalva or cough were used.
The left atrium and ventricle were not specifically focused
on to facilitate detection of subtle echogenic signals in the
right side of the heart. The primary end point was the
appearance of any echogenic phenomena in the heart.
These were characterized as trace amounts when sporadic
fleeting signals were observed, moderate when a repeating
speckled pattern of bright signals scattered on a hypo
echoic background were seen, and as a bolus when bright
reflective signals filled the entire heart chamber.
Patients remained in the clinic for 20 to 30 minutes
after their injection; initially with their leg elevated for 10
minutes, then while a nurse fitted and applied a compres-
sion bandage along with a 30- to 40-mm Hg support
stocking and reviewed post-treatment instructions. At the
time of treatment, patients were asked to report any un-
usual sensations they experienced during or after injection
without suggesting any particular symptom to look for.
Other authors have recommended this as a useful method
to gather patient information on the side effects of treat-
ment.20 Nevertheless, upon discharge from the office, pa-
tients were advised to contact the clinic without delay if
they experienced leg pain or swelling, chest pain, dyspnea,
or any other adverse symptoms.
Patients were seen in follow-up 4 weeks after the injec-
tion and were queried about any problems since the previ-
ous visit. The treated leg was physically examined, and a
duplex ultrasound assessment was performed. The entire
length of the treated vein was examined for compressibility
with application of probe pressure and was also checked for
forward and reverse flow during distal compression and
release using color flow and spectral Doppler analysis. Any
segment of treated vein that demonstrated compressibility
or the presence of flow was classified as incompletely oc-
cluded for purposes of early outcome assessment. Incom-
plete sclerosis of a small section of the treated vein was not
regarded as a failure of the treatment session as long as the
remainder of the vein was completely occluded. Such small
segments of vein were easily injected as part of a follow-up
appointment to treat other varicosities.
The initial cohort (group 1) consisted of 20 patients
who received an ultrasound-guided foam sclerotherapy in-
jection while in a supine position with the leg level. Proxi-
mal progression of the foam was monitored by ultrasound,
and pressure was applied at the groin when the foam was
observed to reach the saphenofemoral junction. Occlusion
of the junction was performed with either the ultrasound
probe or digital pressure. Ten of these patients were in-
jected with air-based foam and 10 were injected with
CO2-based foam.
After assessment of the first 20 patients, the injection
technique was changed to involve leg elevation of 30° to
45° for 1 to 2 minutes before foam injection. As in the first
group, pressure was applied at the saphenous junction after
injection. Groin pressure was maintained for 3 to 4 min-utes. In this second group (group 2) of 19 patients, 18 were
treated with foam using room air, and one was treated with
CO2-based foam.
A third group of 19 patients (group 3) was treated with
leg elevation before injection, but no pressure was applied
to the saphenofemoral junction. Progress of the foam
downstream from the injection site was monitored with
ultrasound, and the injection was discontinued when the
foam reached a point immediately distal to the femoral
vein. Air-based foam was used to treat 18 patients in group
3, and CO2-based foam was used in one.
The incidence of echogenic signals in the right heart
chambers after injection was compared among the three
groups using the Fisher exact test (two-sided). Foam vol-
umes used among the three groups were compared using
one-way analysis of variance. Foam volumes used in the
positive and negative echocardiography subjects in group 3
were compared using an independent sample t test (two-
tailed). The Fisher exact test was used to check for any
statistically significant relationships between group and lo-
cation of injection on the leg or between group and initial
success of treatment.
RESULTS
No patients complained of chest pain, cough, migraine,
visual disturbance, or other neurologic symptoms after
injection. There were no other major complications such as
deep vein thrombosis or skin ulceration. Echogenic signals
were not observed in the left heart, although the left atrium
and ventricle were not specifically focused on during car-
diac scanning to facilitate better visualization of the right
heart chambers. Also, no provocative maneuvers were used
to precipitate right to left shunting. As a consequence, no
atrial septal or ventricular septal defects were observed,
although small defects or shunts could have remained
undetected.
The three groups were equivalent in patient age and
foam volumes used (Table I). However, a statistically non-
significant trend towards lower foam volume was noted in
group 3. This corresponded with the observation that a
dramatic reduction in vein diameter often occurred after leg
elevation. For the purpose of calculating the probability of
a type II error in comparing mean foam volumes used
between groups 1 and 3, we assumed that the foam volume
required to fill a vein segment approximated the current
Table I. Foam volumes used in each group
Group Patient, No.
Volume, mL
Mean (SD) Range
1 20 5.09 (1.58) 2.2-8.0
2 19 4.78 (2.29) 2.0-12.0
3 19 4.06 (1.32) 2.0-6.0
Analysis of variance: F2,55  1.706, P  .191 which is not statistically
significant at the 0.05 level.intravascular volume of that vein segment. The true mean
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realistically estimated as one-half to one-third of the true
vein volume when the leg is horizontal. Therefore, the
probability of a type II error in comparing the mean foam
volumes used for group 1 (leg horizontal) vs group 3 (leg
elevated) is P (type II error)  .139 based on the assump-
tion that the potential volume of the saphenous vein in an
elevated limb is one-half of the potential volume in the vein
when the limb is horizontal. However, if the true mean
potential vein volume for an elevated limb is assumed to be
one-third of that with the leg horizontal, then P (type II
error)  .002075. Most patients in all three groups were
injected in the middle or distal thigh region of the saphe-
nous vein (Table II). There was no significant difference in
the location of injection among the three groups by the
Fisher exact test (P  .478). Thus, it is unlikely that the
location of the injection influenced the probability of ob-
serving echogenic cardiac signals in the different groups.
No significant difference existed in the incidence of
echogenic phenomena observed in the right heart between
patients injected with the leg horizontal and pressure at the
saphenofemoral junction (group 1) and patients injected
with the leg elevated while pressure was applied at the
saphenous junction (group 2). There was a highly signifi-
cant difference in the incidence of echogenic phenomena
seen in the right heart after injection with the leg flat and
pressure at the saphenofemoral junction (group 1) com-
pared with injection with the leg elevated and no pressure at
the groin (group 3). The incidence of echogenic cardiac
signals was also significantly higher in group 2 after pressure
release at the junction during leg elevation compared with
group 3 where the leg was elevated before injection but the
saphenous junction was not compressed (Table III). Car-
diac signals were detected in 50% of patients in group 3.
There was no significant difference in foam volume be-
tween the patients in group 3 who had evidence of foam in
the right heart and those who did not (Table IV).
Echogenic cardiac phenomena were observed in all
group 1 patients after the release of groin compression
regardless of whether the injected sclerosant foam was
produced with air or CO2 (Fig 1). Ten of the 12 patients
injected with CO2 foamwere in group 1, one patient was in
group 2, and one patient was in group 3. The patient in
group 2 demonstrated a bolus of echogenic material in the
right heart after CO2 foam injection, but the patient in
group 3 had a negative result on the cardiac study. Thus, 11
of the 12 patients injected with CO2 foam showed evidence
Table II. Location of saphenous vein injection for
each leg
Group Distal thigh Middle thigh Proximal thigh
1 17 1 2
2 12 5 2
3 13 4 2of echogenic cardiac phenomena after injection. Ten of the11 CO2 foam patients with positive results on cardiac
studies demonstrated a foam bolus in the right heart after
injection, whereas one had scant signals.
In 50% of cases among group 1 and 2 patients
Table III. Echogenic phenomena observed in right
atrium and ventricle post foam injection
Echogenic cardiac
phenomena
Group 1: Leg
horizontal,
SFJ
compression
Group 2: Leg
elevated, SFJ
compression
Group 3: Leg
elevated, no
SFJ
compression
N  20 N  19 N  19
Positive, No. (%) 20 (100) 16 (84) 9 (47)
Negative, No. (%) 0 3 (16) 10 (53)
SFJ, Saphenofemoral junction.
Group 1 vs 2: Fisher exact test P  .106.
Group 1 vs 3: Fisher exact test (2-sided) P .001, which is very significant.
Group 2 vs 3: Fisher exact test (2-sided) P  .038.
Table IV. Foam volumes injected in positive and
negative cardiac studies in group 3 (leg elevated with no
compression at saphenofemoral junction)
Echogenic cardiac
phenomena Patients
Volume, mL
Mean (SD) Range
Positive 9 3.53 (1.06) 2.0-5.2
Negative 10 4.54 (1.40) 2.0-6.0
t17  1.751; P  .098.
Fig 1. Ultrasound of patient’s heart immediately after release of
compression at the saphenofemoral junction shows echogenic
phenomena filling the right atrium and ventricle. The great saphe-
nous vein had been previously injected with 5.2 mL of sclerosant
foam composed of air and 2% sodium tetradecyl sulfate while the
leg was horizontal and the junction was compressed.(groups treated with junctional occlusion during injec-
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genic phenomena showed a concentrated bolus suspected
to be foam particles with release of compression at the
saphenofemoral junction (Figs 1-3). A bolus was seen in 13
of 20 positive patients injected with the leg horizontal
(group 1) and in eight of 16 positive patients injected with
the leg elevated (group 2). The remainder of the group 1
and 2 patients with positive scans had episodes of scant
echogenic signals or moderate hyperechoic speckling visi-
ble in the right atrium and ventricle. A bolus could occur
even after injection of very small amounts of foam, some-
times as little as 2.2 mL. This high frequency of echogenic
boluses was in contrast to the patients with positive cardiac
scans who were injected during leg elevation with no
compression of the saphenous junction (group 3). Among
these patients, only one of nine patients with a positive scan
showed a small bolus during quiet leg elevation. However,
leg muscle contraction created a bolus in a second patient,
and leg lowering after 3 minutes produced a bolus in a third
patient. Otherwise, only scant or moderate intensity signals
were observed in positive group 3 subjects.
Short-term therapeutic outcome was assessed with du-
plex ultrasound at 1 to 2 months after treatment. In the 55
lower extremities that were available for follow-up exami-
nation, 54 veins (98%) were occluded throughout75% of
their treated length after one injection. By the Fisher exact
test, no statistically significant relationship was noted be-
tween group and efficacy of treatment (P  .301). How-
ever, it was our impression that limbs injected during leg
Fig 2. Ultrasound taken 14 seconds after release of occlusion at
the saphenofemoral junction shows that foam is still present in the
left atrium and is clearing from the left ventricle.elevation without occlusion at the saphenofemoral junctionwere more likely to present with a short open segment of
vein just below the saphenofemoral junction when seen at
the 1-month follow-up. In subsequent applications of this
technique, the initial injection was performed in the prox-
imal third of the vein in the thigh and this resulted in
improved closure close to the saphenous junction.
DISCUSSION
Echogenic phenomena in the central venous circula-
tion and specifically in the right heart appear to be a very
common occurrence after foam sclerotherapy, even with
modest quantities of foam injected. These signals are prob-
ably foam bubbles, but may represent particulate matter
such as clumps of endothelial cells. These episodes occurred
with both air- and CO2-based foam when the limb was
injected in a horizontal position and occlusion of the saphe-
nofemoral junction was performed. Only two patients were
injected with CO2 foam when the leg was elevated, so the
combined effect of CO2 foam and leg elevation could not
be assessed. Occlusion of the saphenofemoral junction
tended to result in a bolus of foam being released into the
central venous circulation when groin pressure was re-
moved, even after 3 to 5 minutes of occlusion. It can be
speculated that junctional compression may simply dam up
foam particles, which are then released en mass when the
pressure is removed. Release of pressure may also create a
suction that aspirates foam from the proximal great saphe-
nous vein into the common femoral vein.
It is quite probable that foam particles were also passing
through the right heart in the cardiac studies when no
signals were seen but were too few to detect with ultra-
sound scanning. It is reasonable to hypothesize that in the
Fig 3. Ultrasound shows that the right heart is clear of foam at 1
minute 45 seconds after release of occlusion at the saphenofemoral
junction.setting of a right to left shunt, small, less cohesive quantities
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a lower risk to the central nervous system than that posed by
a concentrated, more viscous bolus of bubbles. This may
also hold true for the pulmonary microvasculature. Gas
bubbles can persist in treated superficial veins for many
minutes after injection, even when CO2 is used. Tech-
niques that occlude the saphenous junction with either
manual compression or balloon dilatation in conjunction
with foam injection may actually amplify the hazards they
seek to prevent.
Leg elevation before injection has several advantages.
Smaller volumes of foam are generally regarded as safer
than large quantities. In many cases, leg elevation dramat-
ically reduces the diameter of the target vein, thus permit-
ting injection of significantly lower amounts of foam to
achieve treatment of the same length of vein. Because foam
is lighter than blood, leg elevation also facilitates the per-
sistence of foam in the treated vein and reduces the degree
of foammigration into the femoral vein through the saphe-
nofemoral junction. Although details were not included in
the present study, we have consistently observed significant
amounts of foam in the central venous circulation and right
heart if the saphenous vein is injected without compression
at the junction when the leg is in a horizontal position. The
advantages of reduced vein caliber and gravitational effects
on foam movement are lost if foam is injected with the leg
level and subsequently elevated. However, cannulation be-
fore leg elevation is advantageous because it is easier to
obtain venous access with the leg horizontal. A catheter
may be preferable to a needle to avoid loss of access during
leg elevation and permit unhurried foam injection.
CONCLUSION
Ultrasound-guided sclerotherapy of the great saphe-
nous vein with foam sclerosants may be best performed
with the leg elevated and no occlusive pressure at the
saphenofemoral junction to reduce the risk of large
amounts of foam or other particulate migration to the right
heart with the potential for embolization to the central
nervous system when a right to left cardiac shunt is present.
Further study is needed to assess themidterm success of this
technical modification and to confirm the effect of using
foam produced from physiologic gases. More research is
also needed into true nature of the echogenic signals ob-
served and their behavior in the pulmonary circulation.
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